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A B S T R A C T
Background: Various cutaneous manifestations have been observed in patients with COVID-19 infection.
However, overall similarities in the clinical presentation of these dermatological manifestations have not
yet been summarized.
Objective: This review aims to provide an overview of various cutaneous manifestations in patients with
COVID-19 through three case reports and a literature review.
Methods: A literature search was conducted using PubMed, OVID, and Google search engines for original
and review articles. Studies written in the English language that mentioned cutaneous symptoms and
COVID-19 were included.
Results: Eighteen articles and three additional cases reported in this paper were included in this review.
Of these studies, 6 are case series and 12 are case report studies. The most common cutaneous
manifestation of COVID-19 was found to be maculopapular exanthem (morbilliform), presenting in 36.1%
(26/72) patients. The other cutaneous manifestations included: a papulovesicular rash (34.7%, 25/72),
urticaria (9.7%, 7/72), painful acral red purple papules (15.3%, 11/72) of patients, livedo reticularis lesions
(2.8%, 2/72) and petechiae (1.4%, 1/72). Majority of lesions were localized on the trunk (66.7%, 50/72),
however, 19.4% (14/72) of patients experienced cutaneous manifestations in the hands and feet. Skin
lesion development occurred before the onset of respiratory symptoms or COVID-19 diagnosis in 12.5%
(9/72) of the patients, and lesions spontaneously healed in all patients within 10 days. Majority of the
studies reported no correlation between COVID-19 severity and skin lesions.
Conclusion: Infection with COVID-19 may result in dermatological manifestations with various clinical
presentations, which may aid in the timely diagnosis of this infection.
© 2020 Japanese Society for Investigative Dermatology. Published by Elsevier B.V. All rights reserved.
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As of April 20th, 2020, COVID-19 (severe acute respiratory
syndrome coronavirus 2 [SARS-CoV-2] or, previously called 2019-
nCoV) initially reported in Wuhan, China [1] has been diagnosed in* Corresponding author at: Ruth and Bruce Rappaport Faculty of Medicine,
Technion Institute of Technology, 1 Efron St., Bat Galim Haifa, 3525433, Israel.
E-mail address: rdodiukgad@gmail.com (R.P. Dodiuk-Gad).
1 Equal contribution.
https://doi.org/10.1016/j.jdermsci.2020.04.011
0923-1811/ © 2020 Japanese Society for Investigative Dermatology. Published by Elsevmore than 2.4 million people worldwide [2]. The high rate of
infectivity, low virulence and asymptomatic transmission have
resulted in its rapid spread across geographic boundaries, leading
to a pandemic [3]. The outbreak of COVID-19 has been declared a
Public Health Emergency of International Concern by the World
Health Organization (WHO) and presents a great challenge for the
health care communities across the globe [4].
SARS-CoV 2 is an enveloped virus composed of positive sense
single-stranded RNA and belongs to the coronavirus family. [1]
The virus enters cells through the angiotensin converting enzymeier B.V. All rights reserved.
Fig. 1. Cutaneous manifestation of COVID-19 in Case 1.
Fig. 2. (a) Cutaneous manifestation of COVID-19 on trunk in Case 2. (b) Cutaneous
manifestation of COVID-19 on legs in Case 2.
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the primary site of infection for COVID-19, with patients
presenting symptoms ranging from a mild flu-like symptoms
to fulminant pneumonia and potentially lethal respiratory
distress [5].
Interestingly, there have been many COVID-19 cases reporting
cutaneous manifestations [6–23]. The purpose of this article is to
report three relevant cases and provide a literature review of
various cutaneous manifestation in patients with COVID-19.
2. Case 1
A 71-year-old Caucasian woman presented to the Emergency
Department in Milan, complaining of fever, productive cough and
worsening shortness of breath which started 10 days before. The
patient was otherwise healthy with no co-morbidities, medi-
cations or previous adverse drug reactions. She was living in
Milan with her husband, who was diagnosed with COVID-19.
Laboratory tests revealed a normal white blood cells and platelet
count (WBC 6470/mm, PLT 290.000/mmc), normal liver and
kidney function and an increased C-reactive protein (49.4 mg/L).
Blood cultures were negative. Bilateral interstitial pneumonia
was found on chest x-ray. Naso-pharyngeal swab tested for SARS-
CoV-2 RNA amplification resulted positive. She was admitted to
the Infectious Disease Department and started off-label antiviral
therapy with lopinavir/ritonavir and hydroxychloroquine, follow-
ing Italian Society of Infectious and Tropical Diseases (SIMIT)
guidelines and empiric antibiotic therapy with third generation
cephalosporin (ceftriaxone). Other drugs administered during
hospitalization were: rabeprazole, paracetamol, metoclopramide,
dihydrocodeine, lactulose and subcutaneous low molecular
weight heparin. In the subsequent days, she promptly recovered:
she never had fever, we have been able to gradually decrease
oxygen flow and on the 30th of march, antiviral and antibiotic
therapies were discontinued. Over the following days a maculo-
papular itchy rash appeared on the trunk resembling a Grover
disease (Fig. 1).
3. Case 2
A 77-year-old Caucasian woman was admitted to the hospital in
Milan, due to neck lymphonodal enlargement, fever, cough and
diffuse maculopapular exanthem (morbilliform) on the trunk
(Fig. 2a). One day later during hospitalization, she also developed
macular hemorrhagic rash on the legs (Fig. 2b). Naso-pharyngeal
swab tested for SARS-CoV-2 RNA amplification were positive. No
signs of pneumonia were found on the chest x ray. Treatment
consisted of antiviral therapy using lopinavir/ritonavir and
hydroxychloroquine and subcutaneous low molecular weight
heparin. Gradual spontaneous improvement of skin lesions
appeared.
4. Case 3
A 72-year-old Caucasian woman, otherwise healthy, presented
to the Emergency Department in Milan with headache, arthralgia,
myalgia and fever. Four days later, a papular-vesicular, pruritic
eruption appeared on sub-mammary folds, trunk and hips
(Fig. 3). Laboratory examination conducted revealed mild
increase in WBC, C-reactive protein and erythrosedimentation
rate (ESR). COVID-19, tested with naso-pharyngeal swab, was
positive. Chest X ray was negative for pneumonia. Complete
remission of both general and cutaneous manifestations was
observed approximately ten days after the beginning of the
clinical picture.5. Methods
A literature search was conducted using PubMed, OVID and
Google search engines for original and review articles published
since the onset of the current COVID-19 epidemic to April 20, 2020.
Search terms “COVID-19”, “2019-nCoV”, “SARS-CoV-2” and “coro-
navirus” were used in combination with “skin”, “dermatology”,
“cutaneous”, “urticaria” and “rash”. We also performed extensive
hand searching of reference lists of relevant papers and reports.
The studies that did not mention cutaneous symptoms or did not
include any relevant information in the English language were
excluded.
We extracted the following data from included studies: author,
publication year, region, number of participants with skin signs,
age, sex, suspected or confirmed status for COVID-19, cutaneous
signs and its location, timeline and healing duration, associated
symptoms, correlation with COVID-19 severity with skin lesions
and treatments for COVID-19 infection. When extracting
Fig. 3. Cutaneous manifestation of COVID-19 in Case.
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compare findings and reach consensus. Where consensus was not
reached, an independent researcher was consulted. We also
searched for grey literature including advisories from professional
societies, expert commentaries, blogposts, magazine articles,
newspaper articles and social media posts to retrieve relevant
information. The information from grey literature was not included
in the results section, however, it has been summarized in the
Supplemental File 1.
6. Results
Eighteen articles and three additional cases (reported in this
review) that met the aforementioned inclusion criteria were
summarized in this review. All studies were published during
February and April 2020, with 61.1% of articles published in April.
There are 6 case series [6–9,16,20], and 12 case reports [10–15,
17–19,21–23]. The mean patient age was 53.6 years, with patients
between 15 days and 84 years of age. Males accounted for 38.9% of
reported cases, females accounted for 27.8% of cases, and the sex of
37.5% cases was not reported. In terms of COVID-19 diagnosis, 2.8%
patients were suspected cases and 97.2% were confirmed cases.
Table 1 summarizes the cases with COVID-related cutaneous
manifestations in the included articles.
A generalized macular or maculopapular exanthem (morbilli-
form) appeared to be the most common cutaneous manifestation
in COVID-19, with 36.1% (26/72) of patients presenting such lesions
on their skin. A papulovesicular rash (vesicles) was seen in 34.7%
(25/72) of patients. Urticaria occurred in 9.7% (7/72) of reported
patients, and the presence of painful acral red purple papules with
or without vesicles was seen in 15.3% (11/72) of patients overall.
Lastly, 2.8% (2/72) presented with livedo reticularis lesions, and 1
patient (1.4%) presented with petechiae. Of the 72 cases, lesion
location was reported in 67 patients, with the majority of lesions
being found on the trunk, hands and feet. Overall, 69.4% (50/72) of
patients experienced lesions on the trunk. Additionally, 19.4%
(14/72) of patients experienced cutaneous manifestations in the
hands and feet.
The timing of skin lesion development ranged between
patients, from development 3 days before COVID-19 diagnosis to
13 days after diagnosis. In the examined cases, 12.5% (9/72) of
patients presented with cutaneous lesions at diagnosis or onset of
COVID-19 symptoms, while 69.4% (50/72) of patients presented
with lesions after the onset of respiratory symptoms or of COVID-
19 diagnosis. The timing of skin lesion development was not
reported in 18.1% (13/72) of patients. Of the 49 patients who
developed lesions after respiratory symptom onset or of COVID-19
diagnosis, 74.0% (37/50) developed cutaneous pathology within 7
days, and 6.0% (3/50) reported lesions after 7 days. Of the 50 cases
with reported healing times, 100% of patients reported healing of
cutaneous lesions, with healing times up to 10 days. 48.0% of
lesions healed within 7 days (24/50) and 50.0% of lesions healedafter 7 days (25/50), and healing time was unspecified for one case
(2.0%).
Five studies reported on the possible association between
COVID-19 and skin lesion severity in 23 patients. In 21 patients
(91.3%), the severity of cutaneous lesions was unlikely to be or was
not correlated with COVID-19 severity. Contrarily, in 2 separate
reports by Mahé [13] and Estébanez [15], COVID-19 and skin lesion
severity were linked in 2 patients (8.7%). Also, in most of the
included studies, histological findings were not reported.
7. Discussion
Dermatologic manifestations of COVID-19 are rare, with
common clinical features including fever, dry cough, shortness
of breath, myalgia and fatigue seen in relatively large-scale case
studies of COVID-19 pneumonia patients [12,24–26]. Skin man-
ifestations were reported only in case reports and two case series.
In this review, we summarized the information of all the 72 COVID-
19 patients with cutaneous manifestations, as reported in the
literature (Table 1).
The most prominent case study of cutaneous manifestations of
COVID-19 published by Recalcati et al. [7] in Lombardy, Italy
included 88 patients. In this study, 20.4% of the confirmed COVID-
19 patients (18/88) had developed cutaneous manifestations. It
was found that most cutaneous presentations were erythematous
rash (77.8% or 14/18) with few cases of urticaria (16.7% or 3/18) and
vesicle formation (5.6% or 1/18). These findings reflect a similar
distribution of cutaneous manifestations as seen in our review.
Cutaneous manifestations are important in the diagnosis of
various infectious diseases, such as toxic shock syndrome,
meningococcemia, rickettsial diseases, measles, and scarlet fever
[27–31]. As COVID-19 has a tendency to produce asymptomatic
cases for up to 14 days after infection, cutaneous manifestations
may serve as an indicator of infection, aiding in timely diagnosis. In
this review, 12.5% (9/72) of patients presented with cutaneous
lesions at onset. Furthermore, physicians’ awareness of the
cutaneous symptoms related to COVID-19 infection is critical in
preventing misdiagnosis of disease, such as the misdiagnosis of
dengue as reported by Joob et al. [10]
The mechanisms of COVID-19 cutaneous disturbances are not
yet well known, but some common theories are prevalent. It can be
postulated that the viral particles present in the cutaneous blood
vessels in patients with COVID19 infection could lead to a
lymphocytic vasculitis similar to those observed in thrombophilic
arteritis induced by blood immune complexes that activate
cytokines. Keratinocytes may be a secondary target after Langer-
hans cells activation, inducing a spectrum of different clinical
manifestation [6,32]. It can be postulated that the virus does not
target the keratinocyte, but rather immune response to infection
leads to Langerhans cells activation, resulting in a state of
vasodilation and spongiosis [32]. Further theories suggest livedo
reticularis-resembling manifestations can result due the accumu-
lation of microthromboses originating in other organs, thus
reducing blood flow to the cutaneous microvasculature system
[8]. Similarly, low grade disseminated intravascular coagulation
and hypoxia-related accumulation of deoxygenated blood in
venous plexes may further explain such manifestations [8].
Additionally, pauci-inflammatory thrombogenic vasculopathy
with deposition of C5b-9 and C4d as well as co-localization of
these with COVID-19 spike glycoproteins was reported by Magro
et al. [33]. It is still unclear whether cutaneous symptoms are a
secondary consequence of respiratory-related infection or a
primary infection of the skin itself. It is more likely that a
combination of such mechanisms is responsible for the cutaneous
manifestations found in COVID-19+ individuals.
Table 1
Characteristics and cutaneous manifestations of suspected and confirmed COVID-19 cases published in scientific literature.
Author,
Publication
Year
Region Patients
with
Skin
Signs (n)
Age, Sex Suspected
or
Confirmed
COVID-19
Cutaneous Manifestations
Signs (n) Location Timing Associated Symptoms Healing
Duration
Correlation
of COVID-19
Severity with
Skin Lesions
Treatments for COVID-19
Infection
Gianotti,
2020 [6]
Milan, Italy 5 Cases 1,
2, 4, 5:
NR, NR
Case 1-5: C Case 1: Exanthema Case 1: Trunk and
limbs
NR NR NR NR NR
Case 3:
NR, M
Case 2: Purpuric maculo-
papulo-vesicular rash
Case 2: NR
Case 3: Papular
erythematous exanthema
Case 3, 4, and 5:
Trunk
Case 4 and 5: Diffuse
maculopapular eruption
clinically suggestive for
Grover disease
Recalcati,
2020 [7]
Lombardy,
Italy
18 NR C Erythematous rash (14),
Widespread urticaria (3),
chickenpox-like vesicles (1)
Trunk 8 developed at onset, 10
after hospitalization
Little to no itching Healed within
a few days
No
correlation
seen with
disease
severity
NR
Manalo
2020 [8]
Atlanta,
Georgia
2 Case 1:
67, M
Case 1,2: C Case 1: Transient non-
pruritic blanching
unilateral livedoid patch
resembling livedo
reticularis
Case 1: Right
anterior thigh
Case 1: Symptoms began 7
days after initial onset of
COVID-19 symptoms, 3
days prior COVID-19
diagnosis
Case1,2: NR Case 1: 19
hours
(eruption)
NR NR
Case 2:
47, F
Case 2: Unilateral
asymptomatic rash
resembling livedo
reticularis
Case 2: Right leg Case 2: 10 days after testing
positive for COVID-19
Case 2: 20
minutes
Zhang 2020
[9]
Wuhan,
China
7 Median
age of
59, 4 M/
3F
C Acro-ischemia
presentations including
finger/toe cyanosis, skin
bulla and dry gangrene
Extremities Median time 19 days (11-23
days)
NR NR NR Low molecular weight
heparin treatment
Joob 2020
[10]
Thailand 1 NR, NR C Skin rash with petechiae NR NR None NR NR NR
Jimenez
2020 [11]
Madrid,
Spain
1 84, F C Erythemato-purpuric,
millimetric, coalescing
macules
Flexural regions,
peri-axillary
3 days of hospitalization, 11
days since onset
NR NR Unlikely Hydroxychloroquine
and lopinavir/ritonavir
Hunt 2020
[12]
New York,
USA
1 20, M C Diffuse, morbilliform,
maculopapular, and
nonpruritic rash
Trunk and
extremities sparing
the face
Along with fever, before
diagnosis
NR NR NR NR
Mahé 2020
[13]
Colmar,
France
1 64, F C Erythematous rash Antecubital fossa,
then to the trunk
and axillary folds
Four days after fever NR Day 9 of
disease
Yes Paracetamol
Fernandez
2020 [14]
Madrid,
Spain
1 32, F C Urticariform rash NR 6 days after the onset of
symptoms
None Improvement
in 5 day-
period
NR Hydroxychloroquine
and azithromycin
Estébanez
2020 [15]
Spain 1 28, F C Pruritic lesions/ Confluent
erythematous-yellowish
papules
Heel 13 days after being
diagnosed
Lesions persisted and
became erythematous
plaques that were both
hardened and pruritic
10 days Yes Paracetamol
Zhang 2020
[16]
Wuhan,
China
2 57 years
(25-87),
C Urticaria NR NR NR NR Unlikely NR
78
 
M
.
 Sachdeva
 et
 al.
 /
 Journal
 of
 D
erm
atological
 Science
 98
 (2020)
 75
–81
71 M/
69F
Henry 2020
[17]
Orléans,
France
1 27, F C Disseminated
erythematous plaques
eruption, urticaria
Face, hand and feet
(acral involvement)
48 hours before onset of
respiratory symptoms
Pruritis NR NR Paracetamol and
antihistamines
Kamali
Aghdam
2020 [18]
Tehran,
Iran.
1 15-
days, M
C Cutaneous mottling NR NR NR 2 days after
entering
hospital.
NR Proper fluid therapy,
oxygen therapy, anti-
biotic therapy by
Vancomycin (10mg/kg/
q8h) and Oseltamivir (3
mg/kg/12 h)
Mazzotta
2020 [19]
Italy 1 13, M S Erythemato-violet,
rounded lesions of 5-15
mm in diameter, with
blurred limits
Plantar surface of
1st right toe and
dorsal surface of the
2nd toe on both feet
NR Intense itching and
burning on the foot
lesions
After a few
days
NR NA
Alramthan
2020 [20]
Qatar 2 Case 1:
27, F
C Case 1,2: Acral ischemic
lesions presenting as red-
purple papules
Case 1,2: Dorsal
aspect of fingers
bilaterally
NR NR NR NR NR
Case 2:
35, F
Najarian
2020 [21]
New
Jersey, USA
1 58, M C Erythematous macules
with islands of normal
appearing skin between
them, arranged in a
morbilliform pattern
Legs, thighs,
forearms, arms,
shoulders, back,
chest, abdomen
1 day after onset of
respiratory symptoms
Pain in legs and hands 1 day NR Azithromycin (500 mg
first day, 250 mg 4
days), benzonatate 100
mg every 6 hours
Kolivras
2020 [22]
Brussels,
Belgium
1 23, M C Violaceous, infiltrated
plaques on an
erythematous background
Dorsal aspect of
toes and lateral
sides of feet
3 days after onset of
respiratory symptoms
Pain NR NR NR
Marzano
2020 [23]
Italy 22 Median
age 60,
16 M/6F
C Varicella-like
papulovesicular exanthem
Trunk, limbs Median latency time from
systemic symptoms to
exanthem was 3 days
(range of -2 to 12 days)
Itching (n = 9) Median
duration was
8 days (range
4 to 15 days)
NR NR
Present
Case 1
Milan, Italy 1 71, F C Maculo-papular itchy rash
resembling Grover disease
Trunk Within days of
discontinued treatment
Itching NR NR Lopinavir/ritonavir and
hydroxychloroquine.
Other administered
drugs include:
rabeprazole,
paracetamol,
metoclopramide,
dihydrocodeine,
lactulose and
subcutaneous low
molecular weight
heparin.
Present
Case 2
Milan, Italy 1 77, F C Diffuse maculopapular
exanthem (morbilliform),
macular hemorrhagic rash
Trunk, legs First dermatological
examination revealed
guttate psoriasis,
symptoms presenting four
days later, lesions
presenting five days later
NR Progressive
healing seen
with
treatment
NR Lopinavir/ritonavir and
hydroxychloroquine
and subcutaneous low
molecular weight
heparin
Present
Case 3
Milan, Italy 1 72, F C Papular-vesicular, pruritic
eruption
Sub-mammary
folds, trunk, hips
4 days after onset of
symptoms
NR 10 days after
onset
NR NR
NR: not reported; M: male; F: female; y: years; S: suspected case; C: confirmed case.
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80 M. Sachdeva et al. / Journal of Dermatological Science 98 (2020) 75–81There are several limitations that must be considered for this
literature review. Firstly, the small sample size used in this analysis
restricts the ability to draw strong conclusion applicable to whole
populations. Additionally, since scientific understanding of COVID-
19 and associated dermatological symptoms is currently evolving
at this stage, the information contained in this review is based
mainly on the limited early experience with COVID-19. Due to
limitations in the availability of COVID-19 literature, the recency of
the COVID-19 outbreak, and language-related exclusion criteria,
this paper only examines 72 cases of COVID-19 related cutaneous
pathologies. Lastly, we must take into account the possibility of
dermatologic side effects experienced from medications used by
participants.
Given the current collection of evidence, it is suggested that
COVID-19 can have dermatological manifestations. As a result,
physicians should be aware of these important clinical manifes-
tations that may aid in the timely diagnosis of COVID-19 infection.
However, further literature and research is required to validate and
elucidate an understanding of COVID-19 related cutaneous
manifestations.
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